{"schema_version":"1.0","type":"article","title":"Asia's Protein Degraders After First PROTAC","url":"https://drugnews.com.tw/articles/2026-11-10-asia-protein-degraders-landscape-veppanu-beone-astellas-anhorn-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-11-10-asia-protein-degraders-landscape-veppanu-beone-astellas-anhorn-en.md","lang":"en","date":"2026-11-10","publish_at":"2026-11-10T15:34:20+08:00","updated_at":"2026-11-10","category":"商業分析系列","topic":"商業分析系列","tags":["protein degrader","PROTAC","Veppanu","tacabrutideg","setidegrasib","AnHorn AH-001","Kintor GT20029","Asia biotech"],"summary":"BeOne said on November 5 that its BTK degrader tacabrutideg met a pivotal Phase 2 goal, with a filing planned for mid-2027, while Veppanu, the first approved PROTAC, earned Arvinas only $0.5 million in Q3 2026 royalties. Astellas has a KRAS G12D degrader in Phase 3, and Taiwan's AnHorn is pursuing a topical AR degrader for hair loss.","key_points":["Veppanu (vepdegestrant) was approved by the FDA on 2026-05-01 as the first PROTAC; Arvinas reported Q3 2026 revenue of $0.5 million, all Rigel royalties.","BeOne said on 2026-11-05 that the pivotal Phase 2 portion of CaDAnCe-101 for tacabrutideg met its primary endpoint, with a filing planned for mid-2027, alongside its Phase 3 (NCT06846671, 250 patients); Astellas's setidegrasib Phase 3 (NCT07409272) plans 614 patients.","AnHorn Medicines completed a 64-subject Phase 1 of topical AR degrader AH-001 (NCT06927960) for androgenetic alopecia; Kintor's GT20029 completed a 180-patient China Phase 2 on 2024-06-30."],"facts":[],"sections":["Key takeaways","Key numbers (with sources)","01 | Degraders don't block a protein, they throw it away","02 | Lesson from the first approval: degradation alone doesn't make a blockbuster","03 | Asia's two Phase 3 bets both target places where inhibitors fail","04 | Taiwan: AnHorn goes topical, away from systemic oncology","05 | Three things to watch","References"],"references":[{"title":"FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer","source":"U.S. FDA","date":"2026-05-01","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vepdegestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast"},{"title":"Arvinas Q3 2026 earnings release (Form 8-K","source":"Arvinas / SEC","date":"2026-11-03","url":"https://www.sec.gov/Archives/edgar/data/0001655759/000162828026069101/q32026earningsrelease.htm"},{"title":"BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates","source":"BeOne Medicines","date":"2026-11-05","url":"https://www.biospace.com/press-releases/beone-medicines-announces-third-quarter-2026-financial-results-and-business-updates"},{"title":"Nurix Therapeutics to Present New and Updated Data of Bexobrutideg (NX-5948) at the 68th ASH Annual Meeting","source":"Nurix Therapeutics","date":"2026-11-05","url":"https://globenewswire.com/news-release/2026/11/05/3396262/0/en/nurix-therapeutics-to-present-new-and-updated-data-from-ongoing-phase-1a-1b-trial-of-bexobrutideg-nx-5948-in-relapsed-refractory-cll-sll-at-the-68th-ash-annual-meeting-and-expositi.html"},{"title":"NCT06846671 tacabrutideg in CLL/SLL","source":"ClinicalTrials.gov","date":"2026-09-28","url":"https://clinicaltrials.gov/study/NCT06846671"},{"title":"NCT07409272 setidegrasib in pancreatic cancer","source":"ClinicalTrials.gov","date":"2026-11-03","url":"https://clinicaltrials.gov/study/NCT07409272"},{"title":"NCT06927960 AH-001 topical SAD/MAD","source":"ClinicalTrials.gov","date":"2025-12-19","url":"https://clinicaltrials.gov/study/NCT06927960"},{"title":"NCT06692465 GT20029 in androgenetic alopecia","source":"ClinicalTrials.gov","date":"2024-11-18","url":"https://clinicaltrials.gov/study/NCT06692465"},{"title":"NCT07516093 bexobrutideg Phase 3","source":"ClinicalTrials.gov","date":"2026-08-31","url":"https://clinicaltrials.gov/study/NCT07516093"},{"title":"NCT06764485 BMS-986365 Phase 3","source":"ClinicalTrials.gov","date":"2026-09-30","url":"https://clinicaltrials.gov/study/NCT06764485"},{"title":"NCT06155084 HP518","source":"ClinicalTrials.gov","date":"2025-12-22","url":"https://clinicaltrials.gov/study/NCT06155084"},{"title":"NCT06555068 HRS-1358","source":"ClinicalTrials.gov","date":"2026-10-22","url":"https://clinicaltrials.gov/study/NCT06555068"},{"title":"NCT06590961 UBX-303061","source":"ClinicalTrials.gov","date":"2026-10-21","url":"https://clinicaltrials.gov/study/NCT06590961"},{"title":"NCT07100938 BGB-45035","source":"ClinicalTrials.gov","date":"2026-05-28","url":"https://clinicaltrials.gov/study/NCT07100938"}],"images":[{"alt":"Figure 1 | How a degrader sends a disease protein to the cell's recycling bin","url":"https://drugnews.com.tw/assets/articles/asia-protein-degraders-landscape-veppanu-beone-astellas-anhorn-en/figure-01.png"},{"alt":"Figure 2 | Asian and global degraders on one scale","url":"https://drugnews.com.tw/assets/articles/asia-protein-degraders-landscape-veppanu-beone-astellas-anhorn-en/figure-02.png"},{"alt":"Figure 3 | How far degraders have advanced, by country","url":"https://drugnews.com.tw/assets/articles/asia-protein-degraders-landscape-veppanu-beone-astellas-anhorn-en/figure-03.png"},{"alt":"Figure 4 | Topical AR degraders: AnHorn vs Kintor","url":"https://drugnews.com.tw/assets/articles/asia-protein-degraders-landscape-veppanu-beone-astellas-anhorn-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/asia-protein-degraders-landscape-veppanu-beone-astellas-anhorn-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-11-10）。Asia's Protein Degraders After First PROTAC。https://drugnews.com.tw/articles/2026-11-10-asia-protein-degraders-landscape-veppanu-beone-astellas-anhorn-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/","faq":[{"q":"What are the key developments in “Veppanu (vepdegestrant) was approved by the FDA on 2026-05-01 as the first PROTAC”?","a":"Veppanu (vepdegestrant) was approved by the FDA on 2026-05-01 as the first PROTAC; Arvinas reported Q3 2026 revenue of $0.5 million, all Rigel royalties."},{"q":"What are the key developments in “BeOne said on 2026-11-05 that the pivotal Phase 2 portion of CaDAnCe-101 for tacabrutideg met its primary endpoint, with a filing planned for mid-2027, alongside its Phase 3 (NCT06846671, 250 patients)”?","a":"BeOne said on 2026-11-05 that the pivotal Phase 2 portion of CaDAnCe-101 for tacabrutideg met its primary endpoint, with a filing planned for mid-2027, alongside its Phase 3 (NCT06846671, 250 patients); Astellas's setidegrasib Phase 3 (NCT07409272) plans 614 patients."},{"q":"What are the key developments in “AnHorn Medicines completed a 64-subject Phase 1 of topical AR degrader AH-001 (NCT06927960) for androgenetic alopecia”?","a":"AnHorn Medicines completed a 64-subject Phase 1 of topical AR degrader AH-001 (NCT06927960) for androgenetic alopecia; Kintor's GT20029 completed a 180-patient China Phase 2 on 2024-06-30."}]}